Extracellular niche and tumor microenvironment enhance the impact of KRAS inhibitors in pancreatic cancer models.

RB-loss determines selective resistance and novel vulnerabilities in breast cancer modelsRB loss

Extracellular niche and tumor microenvironment enhance the impact of KRAS inhibitors in pancreatic cancer models [RNA-seq]

TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924

Differential responses to selective CDK2 inhibitor BLU-222 is conditioned by tumor suppressors